Thinle Chodon
University of Chicago Medicine Comprehensive Cancer Center · 234 works · 7,465 citations · h-index 27
Top works
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- PD-1 Blockade Expands Intratumoral Memory T Cells
- A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- Keloid-Derived Fibroblasts Are Refractory to Fas-Mediated Apoptosis and Neutralization of Autocrine Transforming Growth Factor-β1 Can Abrogate this Resistance
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
- Keratinocytes Promote Proliferation and Inhibit Apoptosis of the Underlying Fibroblasts: An Important Role in the Pathogenesis of Keloid
- Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
- Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
- Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
- Cancer Immunotherapy Principles and Practice
- Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
- MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro